Login / Signup

High-Dose Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration Resistant to Standard-Dose Brolucizumab.

Jinsoo KimMin Seon ParkBum-Joo ChoSoonil Kwon
Published in: Ophthalmology and therapy (2024)
High-dose brolucizumab was effective in patients who did not respond to standard-dose brolucizumab after switching from previous anti-VEGF agents. Increasing the dosage could offer sustained disease control and reduce the treatment burden for patients with refractory AMD.
Keyphrases
  • age related macular degeneration
  • high dose
  • low dose
  • stem cell transplantation
  • vascular endothelial growth factor
  • endothelial cells
  • risk factors
  • combination therapy
  • smoking cessation